Dr. Schraeml obtained his PhD in Biotechnology at the Martin Luther Universität, Halle-Wittenberg, after which he joined Scil Proteins GmbH in the position of Head of Affilin technology (development of artificial binding proteins). In 2007, he joined Roche Diagnostics GmbH, Penzberg, Germany, where started as Team Lead Biointeraction Analysis and currently holds the position of Director Antigen Design & Protein Expression Technologies. Dr. Schreaml has a vast experience in all facets of real time interaction measurement assays and label-free biosensing technologies, an area which he has been involved in since 1999.